公开(公告)号：JP2012111760A

公开(公告)日：2012-06-14

申请号：JP2011288226

申请日：2011-12-28

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： PATEL JYOTI R ,  SHUAI QI ,  LINK JAMES T ,  ROHDE JEFFREY J ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

IPC: C07C237/24 ,  A61K31/16 ,  A61K31/165 ,  A61K31/18 ,  A61K31/196 ,  A61K31/277 ,  A61K31/40 ,  A61K31/41 ,  A61K31/42 ,  A61K31/44 ,  A61K31/5375 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08 ,  C07D295/08 ,  C07D295/22 ,  C07D401/04

CPC classification number: C07C233/23 ,  C07C235/14 ,  C07C237/24 ,  C07C255/31 ,  C07C255/47 ,  C07C259/16 ,  C07C311/08 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07C317/22 ,  C07C317/30 ,  C07C317/44 ,  C07C323/41 ,  C07C323/60 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D207/48 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08

Abstract: PROBLEM TO BE SOLVED: To provide adamantyl derivatives as an 11-β-hydroxysteroid dehydrogenase (HSD) 1, whose inhibition prevents or decreases the tissue specific amplification of glucocorticoid action thus imparting beneficial effects on blood pressure and glucose- and lipid-metabolism.SOLUTION: Compounds are used which are inhibitors of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-β-hydroxysteroid dehydrogenase Type 1 enzyme, e.g. acylamino-substituted adamantane carboxylic amides, for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 要解决的问题：提供作为11-β-羟基类固醇脱氢酶（HSD）1的金刚烷基衍生物，其抑制可以防止或减少糖皮质激素作用的组织特异性扩增，从而赋予血压和葡萄糖 - 和脂质 - 代谢。 解决方案：使用化合物，其是11-β-羟基类固醇脱氢酶1型酶的抑制剂。 本发明还涉及11-β-羟基类固醇脱氢酶抑制剂1型酶的用途，例如， 用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征以及由过度的糖皮质激素作用介导的其它疾病和病症的酰氨基取代的金刚烷羧酸酰胺。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：WO2006074244A3

公开(公告)日：2006-09-28

申请号：PCT/US2006000210

申请日：2006-01-05

Applicant: ABBOTT LAB ,  PATEL JYOTI R ,  SHUAI QI ,  LINK JAMES T ,  ROHDE JEFFREY J ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

Inventor： PATEL JYOTI R ,  SHUAI QI ,  LINK JAMES T ,  ROHDE JEFFREY J ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

IPC: C07C235/14 ,  A61K31/4402 ,  A61P3/10 ,  C07C317/16 ,  C07C323/41 ,  C07D207/48 ,  C07D213/64 ,  C07D233/54 ,  C07D257/04 ,  C07D261/08

CPC classification number: C07C233/23 ,  C07C235/14 ,  C07C237/24 ,  C07C255/31 ,  C07C255/47 ,  C07C259/16 ,  C07C311/08 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07C317/22 ,  C07C317/30 ,  C07C317/44 ,  C07C323/41 ,  C07C323/60 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D207/48 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：WO2010123838A3

公开(公告)日：2011-03-03

申请号：PCT/US2010031660

申请日：2010-04-20

Applicant: ABBOTT LAB ,  PEDDI SRIDHAR ,  PATEL MEENA V ,  ROHDE JEFFREY J

Inventor： PEDDI SRIDHAR ,  PATEL MEENA V ,  ROHDE JEFFREY J

IPC: C07C261/04 ,  A61K31/26 ,  A61P3/10 ,  A61P25/00 ,  C07C257/14

CPC classification number: A61K31/26 ,  C07C257/14 ,  C07C257/16 ,  C07C261/04 ,  C07C311/46 ,  C07C317/30 ,  C07C327/42 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/18 ,  C07C2602/42 ,  C07C2602/44 ,  C07C2603/74 ,  C07C2603/97 ,  C07D207/277 ,  C07D211/14 ,  C07D213/24 ,  C07D213/26 ,  C07D213/74 ,  C07D231/12 ,  C07D239/42 ,  C07D257/04 ,  C07D261/08 ,  C07D277/42 ,  C07D295/14 ,  C07D307/46 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12

Abstract: The present invention relates to inhibitors of 11- ß-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract translation: 本发明涉及11-β-羟基类固醇脱氢酶1型酶的抑制剂及其在治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征，中枢神经系统疾病和疾病和病症中的用途 这与过量的糖皮质激素有关。

公开(公告)号：WO2006074330A3

公开(公告)日：2007-01-25

申请号：PCT/US2006000402

申请日：2006-01-05

Applicant: ABBOTT LAB ,  ROHDE JEFFREY J ,  SHUAI QI ,  LINK JAMES T ,  PATEL JYOTI R ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  YONG HONG ,  YEH VINCE S ,  KURUKULASURIYA RAVI

Inventor： ROHDE JEFFREY J ,  SHUAI QI ,  LINK JAMES T ,  PATEL JYOTI R ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  YONG HONG ,  YEH VINCE S ,  KURUKULASURIYA RAVI

IPC: C07C233/63 ,  A61K31/165 ,  A61K31/381 ,  A61K31/415 ,  A61K31/42 ,  A61K31/4409 ,  A61P3/04 ,  A61P3/10 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

CPC classification number: C07D207/277 ,  C07C233/11 ,  C07C233/52 ,  C07C233/58 ,  C07C233/63 ,  C07C237/24 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D211/78 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。

公开(公告)号：WO2009026422A2

公开(公告)日：2009-02-26

申请号：PCT/US2008073830

申请日：2008-08-21

Applicant: ABBOTT LAB ,  BITNER R SCOTT ,  BROWMAN KAITLIN E ,  BRUNE MICHAEL E ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JACOBSON PEER ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  LINK JAMES T ,  MADAR DAVID J ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J ,  RUETER LYNNE E ,  SHUAI QI ,  SORENSEN BRYAN K ,  WANG JIAHONG ,  WICKE KARSTEN M ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

Inventor： BITNER R SCOTT ,  BROWMAN KAITLIN E ,  BRUNE MICHAEL E ,  CHEN YIXIAN ,  DINGES JURGEN ,  DRESCHER KARLA ,  JACOBSON PEER ,  JAE HWAN-SOO ,  KURUKULASURIYA RAVI ,  LINK JAMES T ,  MADAR DAVID J ,  PATEL JYOTI R ,  PLIUSHCHEV MARINA A ,  ROHDE JEFFREY J ,  RUETER LYNNE E ,  SHUAI QI ,  SORENSEN BRYAN K ,  WANG JIAHONG ,  WICKE KARSTEN M ,  WINN MARTIN ,  WODKA DARIUSZ ,  YEH VINCE ,  YONG HONG

IPC: A61K31/495 ,  A61K31/44

CPC classification number: C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-ß-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract translation: 用于治疗患有与糖尿病相关的中枢神经系统与衰老和神经变性有关的障碍和缺陷的患者的方法，其包括一般的注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年痴呆症，艾滋病痴呆症，神经变性，抑郁症和精神分裂症的方法，包括向需要这种治疗的患者施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。

公开(公告)号：WO2004060859A3

公开(公告)日：2004-09-02

申请号：PCT/US0338906

申请日：2003-12-08

Applicant: ABBOTT LAB

Inventor： ANDERSON STEVEN N ,  BHATIA PRAMILA ,  KOLASA TEODOZYJ ,  NAKANE MASAKI ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  XIA ZHIREN ,  ZHANG HENRY Q

IPC: C07C323/62 ,  C07D211/16 ,  C07D211/34 ,  C07D211/42 ,  C07D211/46 ,  C07D211/62 ,  C07D213/70 ,  A61K31/165 ,  A61K31/44

CPC classification number: C07D213/70 ,  C07C323/62 ,  C07D211/16 ,  C07D211/34 ,  C07D211/42 ,  C07D211/46 ,  C07D211/62

Abstract: Compounds of formula (I) are useful for increasing cGMP levels in a mammal.

Abstract translation: 式（I）化合物可用于增加哺乳动物中的cGMP水平。

公开(公告)号：MX2011011082A

公开(公告)日：2011-11-04

申请号：MX2011011082

申请日：2010-04-20

Applicant: ABBOTT LAB

Inventor： ROHDE JEFFREY J ,  PEDDI SRIDHAR ,  PATEL MEENA V

IPC: C07C261/04 ,  A61K31/26 ,  A61P3/10 ,  A61P25/00 ,  C07C257/14

Abstract: La presente invención se refiere a inhibidores de la enzima de deshidrogenasa 1 1-ß-hidroxiesteroide tipo 1 y su uso en tratamiento de diabetes tipo 2 dependiente de insulina, resistencia a insulina, obesidad, trastorno de lípidos, síndrome metabólico, trastornos del sistema nervioso central, y enfermedades y condiciones que están relacionadas con glucocorticoides excesivos.

公开(公告)号：NZ555966A

公开(公告)日：2011-03-31

申请号：NZ55596606

申请日：2006-01-05

Applicant: ABBOTT LAB

Inventor： PATEL JYOTI R ,  SHUAI QI ,  LINK JAMES T ,  ROHDE JEFFREY J ,  DINGES JURGEN ,  SORENSEN BRYAN K ,  WINN MARTIN ,  YONG HONG ,  YEH VINCE S

IPC: C07C235/14 ,  A61K31/4402 ,  A61P3/10 ,  C07C317/16 ,  C07C323/41 ,  C07D207/48 ,  C07D213/64 ,  C07D233/54 ,  C07D257/04 ,  C07D261/08

Abstract: The disclosure relates to adamantine-carboxamide derivative compounds of formula (I) which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, wherein the variables are as defined in the specification. The disclosure further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

公开(公告)号：SI1124804T1

公开(公告)日：2006-02-28

申请号：SI9930842

申请日：1999-10-27

Applicant: ABBOTT LAB

Inventor： BLACK LAWRENCE A ,  BASHA ANWER ,  KOLASA TEODOZYJ ,  KORT MICHAEL E ,  LIU HUAQING ,  MCCARTY CATHERINE M ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  COGHLAN MICHAEL J ,  STEWART ANDREW O

IPC: C07D237/00 ,  A61K31/00 ,  C07D405/00 ,  C07D409/00

公开(公告)号：CA2568241A1

公开(公告)日：2005-11-17

申请号：CA2568241

申请日：2005-04-29

Applicant: ABBOTT LAB

Inventor： ROHDE JEFFREY J ,  WODKA DARIUSZ ,  SHUAI QI ,  PATEL JYOTI R ,  LINK JAMES T ,  PLIUSHCHEV MARINA A

IPC: C07D213/06 ,  A61K31/44 ,  A61K31/445 ,  C07C237/04 ,  C07C237/24 ,  C07D207/02 ,  C07D209/08 ,  C07D213/24 ,  C07D213/72 ,  C07D213/74 ,  C07D213/85 ,  C07D223/16 ,  C07D253/06 ,  C07D257/04 ,  C07D277/64 ,  C07D295/15 ,  C07D295/185 ,  C07D471/08 ,  C07D491/04

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.